{"id": "article-37470_0", "title": "Modafinil -- Continuing Education Activity", "content": "Modafinil is a non-amphetamine central nervous system (CNS) stimulant with wakefulness-promoting properties. It is used in the treatment of conditions which cause excessive daytime sleepiness. In the United States, modafinil is FDA-approved for the treatment of the following in adults: narcolepsy, sleep work shift disorder, and obstructive sleep apnea (adjunct to continuous positive airway pressure (CPAP)). It also has several off-label indications. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of modafinil, pertinent for members of the interprofessional team in the treatment of patients with conditions where modafinil has a therapeutic purpose.", "contents": "Modafinil -- Continuing Education Activity. Modafinil is a non-amphetamine central nervous system (CNS) stimulant with wakefulness-promoting properties. It is used in the treatment of conditions which cause excessive daytime sleepiness. In the United States, modafinil is FDA-approved for the treatment of the following in adults: narcolepsy, sleep work shift disorder, and obstructive sleep apnea (adjunct to continuous positive airway pressure (CPAP)). It also has several off-label indications. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of modafinil, pertinent for members of the interprofessional team in the treatment of patients with conditions where modafinil has a therapeutic purpose."}
{"id": "article-37470_1", "title": "Modafinil -- Continuing Education Activity", "content": "Objectives: Identify the mechanism of action of modafinil. Review the approved and off-label indications for modafinil. Summarize the adverse events to modafinil therapy. Outline the importance of collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from therapy with modafinil. Access free multiple choice questions on this topic.", "contents": "Modafinil -- Continuing Education Activity. Objectives: Identify the mechanism of action of modafinil. Review the approved and off-label indications for modafinil. Summarize the adverse events to modafinil therapy. Outline the importance of collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from therapy with modafinil. Access free multiple choice questions on this topic."}
{"id": "article-37470_2", "title": "Modafinil -- Indications", "content": "Modafinil is a non-amphetamine central nervous system (CNS) stimulant with wakefulness-promoting properties. It is used in the treatment of conditions that cause excessive daytime sleepiness.", "contents": "Modafinil -- Indications. Modafinil is a non-amphetamine central nervous system (CNS) stimulant with wakefulness-promoting properties. It is used in the treatment of conditions that cause excessive daytime sleepiness."}
{"id": "article-37470_3", "title": "Modafinil -- Indications -- FDA-approved Indications", "content": "Narcolepsy: First-line treatment;\u00a0Modafinil is used to treat the daytime fatigue associated with narcolepsy, and it has not been shown to improve symptoms of cataplexy. Sleep Work Shift Disorder: First-line treatment Obstructive sleep apnea: Adjunct to continuous positive airway pressure (CPAP)", "contents": "Modafinil -- Indications -- FDA-approved Indications. Narcolepsy: First-line treatment;\u00a0Modafinil is used to treat the daytime fatigue associated with narcolepsy, and it has not been shown to improve symptoms of cataplexy. Sleep Work Shift Disorder: First-line treatment Obstructive sleep apnea: Adjunct to continuous positive airway pressure (CPAP)"}
{"id": "article-37470_4", "title": "Modafinil -- Indications -- Off-labeled Indications", "content": "Attention-deficit hyperactivity disorder [1] [2] :\u00a0Some evidence of efficacy exists in the pediatric population. A recent study of adult ADHD patients found no benefit of modafinil. [3] Acute unipolar and bipolar depressive episodes [4] Cocaine dependence:\u00a0Evidence regarding the efficacy of modafinil for this purpose appears mixed [5] [6] Cancer-related fatigue:\u00a0Evidence regarding the efficacy of modafinil for this use appears mixed [7] [8] Multiple sclerosis-related fatigues [9] The use of modafinil as a \u201ccognitive enhancer\u201d in healthy subjects has been suggested in the literature; however, the precise benefits and risks associated with this use remain uncertain. [10] [11]", "contents": "Modafinil -- Indications -- Off-labeled Indications. Attention-deficit hyperactivity disorder [1] [2] :\u00a0Some evidence of efficacy exists in the pediatric population. A recent study of adult ADHD patients found no benefit of modafinil. [3] Acute unipolar and bipolar depressive episodes [4] Cocaine dependence:\u00a0Evidence regarding the efficacy of modafinil for this purpose appears mixed [5] [6] Cancer-related fatigue:\u00a0Evidence regarding the efficacy of modafinil for this use appears mixed [7] [8] Multiple sclerosis-related fatigues [9] The use of modafinil as a \u201ccognitive enhancer\u201d in healthy subjects has been suggested in the literature; however, the precise benefits and risks associated with this use remain uncertain. [10] [11]"}
{"id": "article-37470_5", "title": "Modafinil -- Mechanism of Action", "content": "Modafinil is known to be\u00a0a weak inhibitor of dopamine reuptake, which may be its primary clinically important property. It has little to no in vivo affinity for the serotonin (5HT) or norepinephrine (NE) transporters. However, elevated concentrations of NE and 5HT in the prefrontal cortex and hypothalamus have been observed following modafinil administration, possibly as an indirect effect of increased extracellular dopamine. Modafinil exists as a racemic mixture of S- and R-enantiomers. The R-enantiomer is thought to be the source of modafinil\u2019s psychotropic properties and is marketed independently as armodafinil. [12]", "contents": "Modafinil -- Mechanism of Action. Modafinil is known to be\u00a0a weak inhibitor of dopamine reuptake, which may be its primary clinically important property. It has little to no in vivo affinity for the serotonin (5HT) or norepinephrine (NE) transporters. However, elevated concentrations of NE and 5HT in the prefrontal cortex and hypothalamus have been observed following modafinil administration, possibly as an indirect effect of increased extracellular dopamine. Modafinil exists as a racemic mixture of S- and R-enantiomers. The R-enantiomer is thought to be the source of modafinil\u2019s psychotropic properties and is marketed independently as armodafinil. [12]"}
{"id": "article-37470_6", "title": "Modafinil -- Mechanism of Action", "content": "Additionally, modafinil has been postulated to increase signaling in the hypothalamic orexin and histamine neurotransmitter pathways, [13] and animal\u00a0studies have also suggested a glutamatergic effect. [14] A potential advantage of modafinil is its very\u00a0low observed propensity for causing euphoric effects associated with traditional psychostimulants (e.g., cocaine, amphetamine). This has been attributed to differences in its interaction with the dopamine transporter at the molecular level. [15] In several laboratory studies of healthy subjects, modafinil has also been shown to reduce the euphoric effects of cocaine. [16] [17]", "contents": "Modafinil -- Mechanism of Action. Additionally, modafinil has been postulated to increase signaling in the hypothalamic orexin and histamine neurotransmitter pathways, [13] and animal\u00a0studies have also suggested a glutamatergic effect. [14] A potential advantage of modafinil is its very\u00a0low observed propensity for causing euphoric effects associated with traditional psychostimulants (e.g., cocaine, amphetamine). This has been attributed to differences in its interaction with the dopamine transporter at the molecular level. [15] In several laboratory studies of healthy subjects, modafinil has also been shown to reduce the euphoric effects of cocaine. [16] [17]"}
{"id": "article-37470_7", "title": "Modafinil -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Modafinil is readily absorbed after oral administration. It is insoluble in an aqueous solution and therefore cannot be administered intravenously. Maximum plasma concentration is reached 2-4 hours after administration. Metabolism: Modafinil undergoes hepatic metabolism via multiple pathways, including CYP3A4. 80% of the dose is recovered in the urine in the form of metabolites.", "contents": "Modafinil -- Mechanism of Action -- Pharmacokinetics. Absorption: Modafinil is readily absorbed after oral administration. It is insoluble in an aqueous solution and therefore cannot be administered intravenously. Maximum plasma concentration is reached 2-4 hours after administration. Metabolism: Modafinil undergoes hepatic metabolism via multiple pathways, including CYP3A4. 80% of the dose is recovered in the urine in the form of metabolites."}
{"id": "article-37470_8", "title": "Modafinil -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: The elimination half-life of a single dose in healthy subjects is approximately 15 hours. [18] Severe renal and/or hepatic impairment\u00a0is known to\u00a0cause significantly increased steady-state drug concentrations. Dose reduction is recommended in patients with severe hepatic impairment.", "contents": "Modafinil -- Mechanism of Action -- Pharmacokinetics. Elimination: The elimination half-life of a single dose in healthy subjects is approximately 15 hours. [18] Severe renal and/or hepatic impairment\u00a0is known to\u00a0cause significantly increased steady-state drug concentrations. Dose reduction is recommended in patients with severe hepatic impairment."}
{"id": "article-37470_9", "title": "Modafinil -- Administration", "content": "Modafinil is available exclusively in the form of 100 mg and 200 mg oral tablets; the usual dose is 200mg once daily. It is classified as a control substance class IV drug.", "contents": "Modafinil -- Administration. Modafinil is available exclusively in the form of 100 mg and 200 mg oral tablets; the usual dose is 200mg once daily. It is classified as a control substance class IV drug."}
{"id": "article-37470_10", "title": "Modafinil -- Administration -- Adult Dosing", "content": "The recommended dose of modafinil tablets in the treatment of narcolepsy or obstructive sleep apnea is \u00a0200 mg orally administered once a day in the morning. For treatment of shift work disorder, modafinil 200 mg once a day is taken about one hour before the start of the work shift.", "contents": "Modafinil -- Administration -- Adult Dosing. The recommended dose of modafinil tablets in the treatment of narcolepsy or obstructive sleep apnea is \u00a0200 mg orally administered once a day in the morning. For treatment of shift work disorder, modafinil 200 mg once a day is taken about one hour before the start of the work shift."}
{"id": "article-37470_11", "title": "Modafinil -- Administration -- Specific Patient Population", "content": "Pediatric Use : Effectiveness and safety in pediatric patients are not established. Modafinil is not FDA-approved for use in the pediatric population for any indication. Serious skin rashes, including Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM), have been reported with modafinil use in pediatric patients. Geriatric Use: In elderly patients, modafinil and metabolite elimination might be reduced, so consider using lower doses and closely monitor patients.", "contents": "Modafinil -- Administration -- Specific Patient Population. Pediatric Use : Effectiveness and safety in pediatric patients are not established. Modafinil is not FDA-approved for use in the pediatric population for any indication. Serious skin rashes, including Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM), have been reported with modafinil use in pediatric patients. Geriatric Use: In elderly patients, modafinil and metabolite elimination might be reduced, so consider using lower doses and closely monitor patients."}
{"id": "article-37470_12", "title": "Modafinil -- Administration -- Specific Patient Population", "content": "Pregnancy: It is classified as pregnancy category C medicine by FDA. There is no evidence to suggest or exclude harm to the human fetus associated with modafinil. However, an increased risk of abortion and intrauterine growth restriction has been observed in some animal studies. The risks and benefits of therapy during pregnancy should be carefully considered. [19] Lactating Women: It is unknown if modafinil is excreted in breast milk. Use with caution, especially if the newborn infant is exclusively breastfed. [20]", "contents": "Modafinil -- Administration -- Specific Patient Population. Pregnancy: It is classified as pregnancy category C medicine by FDA. There is no evidence to suggest or exclude harm to the human fetus associated with modafinil. However, an increased risk of abortion and intrauterine growth restriction has been observed in some animal studies. The risks and benefits of therapy during pregnancy should be carefully considered. [19] Lactating Women: It is unknown if modafinil is excreted in breast milk. Use with caution, especially if the newborn infant is exclusively breastfed. [20]"}
{"id": "article-37470_13", "title": "Modafinil -- Administration -- Specific Patient Population", "content": "Hepatic Impairment: In patients with severe hepatic impairment, modafinil dose should be reduced by one-half of the usual dosage indicated for the patients. Dose reduction to a maximum of 100mg daily is recommended in patients with severe hepatic impairment. Renal Impairment: Modafinil should be used with caution in patients with severe renal impairment. However, no recommendations for renal dosing exist.", "contents": "Modafinil -- Administration -- Specific Patient Population. Hepatic Impairment: In patients with severe hepatic impairment, modafinil dose should be reduced by one-half of the usual dosage indicated for the patients. Dose reduction to a maximum of 100mg daily is recommended in patients with severe hepatic impairment. Renal Impairment: Modafinil should be used with caution in patients with severe renal impairment. However, no recommendations for renal dosing exist."}
{"id": "article-37470_14", "title": "Modafinil -- Adverse Effects", "content": "Modafinil is generally a well-tolerated stimulant. The most commonly reported adverse effects of modafinil (less than 10% of users) are a headache, nausea, and decreased appetite. Other commonly reported adverse effects (5% to 10% of users) include anxiety, insomnia, dizziness, diarrhea, and rhinitis. [1]", "contents": "Modafinil -- Adverse Effects. Modafinil is generally a well-tolerated stimulant. The most commonly reported adverse effects of modafinil (less than 10% of users) are a headache, nausea, and decreased appetite. Other commonly reported adverse effects (5% to 10% of users) include anxiety, insomnia, dizziness, diarrhea, and rhinitis. [1]"}
{"id": "article-37470_15", "title": "Modafinil -- Adverse Effects", "content": "Regarding serious adverse effects, cases of stevens-johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in postmarketing surveillance. These life-threatening rashes associated with modafinil appear extremely\u00a0rare, although the precise incidence rates are not known. Most of the reported cases have occurred within six weeks of drug initiation. Therefore, any patient who develops a rash during this time frame is advised to notify the prescribing physician immediately. [21]", "contents": "Modafinil -- Adverse Effects. Regarding serious adverse effects, cases of stevens-johnson syndrome, toxic epidermal necrolysis, and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in postmarketing surveillance. These life-threatening rashes associated with modafinil appear extremely\u00a0rare, although the precise incidence rates are not known. Most of the reported cases have occurred within six weeks of drug initiation. Therefore, any patient who develops a rash during this time frame is advised to notify the prescribing physician immediately. [21]"}
{"id": "article-37470_16", "title": "Modafinil -- Adverse Effects", "content": "Abuse Potential :\u00a0In clinical trials, modafinil use produces euphoric and\u00a0psychoactive effects, altering thinking,\u00a0mood, feelings, and\u00a0perception like other CNS stimulants. Assess the risk of potential abuse and use it with caution in patients with a history of drug abuse.", "contents": "Modafinil -- Adverse Effects. Abuse Potential :\u00a0In clinical trials, modafinil use produces euphoric and\u00a0psychoactive effects, altering thinking,\u00a0mood, feelings, and\u00a0perception like other CNS stimulants. Assess the risk of potential abuse and use it with caution in patients with a history of drug abuse."}
{"id": "article-37470_17", "title": "Modafinil -- Adverse Effects", "content": "Withdrawal: In one placebo-controlled clinical trial, after nine weeks of modafinil use, the effects of modafinil withdrawal were observed. No withdrawal symptoms were observed in patients with modafinil treatment cessation during 14 days of observation, but in patients with narcolepsy, sleepiness returned.", "contents": "Modafinil -- Adverse Effects. Withdrawal: In one placebo-controlled clinical trial, after nine weeks of modafinil use, the effects of modafinil withdrawal were observed. No withdrawal symptoms were observed in patients with modafinil treatment cessation during 14 days of observation, but in patients with narcolepsy, sleepiness returned."}
{"id": "article-37470_18", "title": "Modafinil -- Contraindications", "content": "There are few, if any, absolute contraindications to the use of modafinil. However, the following is a list of relative contraindications, cautions, and special considerations:", "contents": "Modafinil -- Contraindications. There are few, if any, absolute contraindications to the use of modafinil. However, the following is a list of relative contraindications, cautions, and special considerations:"}
{"id": "article-37470_19", "title": "Modafinil -- Contraindications", "content": "Dermatological reaction: If serious rash including Stevens-Johnson syndrome develops, discontinue modafinil at the first sign of rash, unless the rash is clearly not drug-related.", "contents": "Modafinil -- Contraindications. Dermatological reaction: If serious rash including Stevens-Johnson syndrome develops, discontinue modafinil at the first sign of rash, unless the rash is clearly not drug-related."}
{"id": "article-37470_20", "title": "Modafinil -- Contraindications", "content": "Angioedema and Anaphylaxis Reactions: If suspected, discontinue modafinil.", "contents": "Modafinil -- Contraindications. Angioedema and Anaphylaxis Reactions: If suspected, discontinue modafinil."}
{"id": "article-37470_21", "title": "Modafinil -- Contraindications", "content": "Multiorgan Hypersensitivity Reactions: If suspected, discontinue modafinil.", "contents": "Modafinil -- Contraindications. Multiorgan Hypersensitivity Reactions: If suspected, discontinue modafinil."}
{"id": "article-37470_22", "title": "Modafinil -- Contraindications", "content": "Persistent Sleepiness: Monitor patients frequently for a degree of sleepiness and, if appropriate, recommend patients to avoid engaging or driving in any other potentially dangerous activity.", "contents": "Modafinil -- Contraindications. Persistent Sleepiness: Monitor patients frequently for a degree of sleepiness and, if appropriate, recommend patients to avoid engaging or driving in any other potentially dangerous activity."}
{"id": "article-37470_23", "title": "Modafinil -- Contraindications", "content": "Cardiovascular disease:\u00a0In patients with preexisting cardiovascular conditions, consider increased monitoring.\u00a0Modafinil is not recommended in patients with documented left-ventricular hypertrophy or a history of the previous cardiotoxicity related to psychostimulant use. It should be used with caution in patients with uncontrolled hypertension, unstable angina, or recent myocardial infarction.", "contents": "Modafinil -- Contraindications. Cardiovascular disease:\u00a0In patients with preexisting cardiovascular conditions, consider increased monitoring.\u00a0Modafinil is not recommended in patients with documented left-ventricular hypertrophy or a history of the previous cardiotoxicity related to psychostimulant use. It should be used with caution in patients with uncontrolled hypertension, unstable angina, or recent myocardial infarction."}
{"id": "article-37470_24", "title": "Modafinil -- Contraindications", "content": "Psychiatric disorders: Modafinil should be used with caution in patients with a history of psychosis and/or mania. Such patients should be monitored for hallucinations, delusions, mania, aggression, and suicidal ideation upon starting modafinil. Discontinuation is advised if these symptoms develop.", "contents": "Modafinil -- Contraindications. Psychiatric disorders: Modafinil should be used with caution in patients with a history of psychosis and/or mania. Such patients should be monitored for hallucinations, delusions, mania, aggression, and suicidal ideation upon starting modafinil. Discontinuation is advised if these symptoms develop."}
{"id": "article-37470_25", "title": "Modafinil -- Contraindications", "content": "Tic disorders: Limited evidence suggests that all CNS stimulants may exacerbate tics in patients with pre-existing tic disorders. A baseline assessment of tics is recommended before initiating treatment. [22]", "contents": "Modafinil -- Contraindications. Tic disorders: Limited evidence suggests that all CNS stimulants may exacerbate tics in patients with pre-existing tic disorders. A baseline assessment of tics is recommended before initiating treatment. [22]"}
{"id": "article-37470_26", "title": "Modafinil -- Monitoring", "content": "There is no requirement for specific monitoring of patients receiving modafinil. However, a variety of drug-drug interactions are possible. Modafinil is\u00a0a substrate of hepatic CYP3A4, a moderate inducer of CYP3A4, and a weak inhibitor of CYP2C19. [18] Modafinil may decrease serum concentrations of other drugs to a clinically significant extent, including\u00a0the following: Antihepaciviral combination products Antiretroviral combination products Clarithromycin Clozapine Cyclosporine Estrogen Derivatives:\u00a0In patients using combined oral contraceptive pills (OCP), the manufacturer recommends that patients use an alternative method of contraception, instead of or in\u00a0addition to OCP, during and until one month after completing modafinil therapy. Guanfacine Lurasidone Nimodipine Opioid medications (e.g., codeine, fentanyl, hydrocodone) Ranolazine Zolpidem", "contents": "Modafinil -- Monitoring. There is no requirement for specific monitoring of patients receiving modafinil. However, a variety of drug-drug interactions are possible. Modafinil is\u00a0a substrate of hepatic CYP3A4, a moderate inducer of CYP3A4, and a weak inhibitor of CYP2C19. [18] Modafinil may decrease serum concentrations of other drugs to a clinically significant extent, including\u00a0the following: Antihepaciviral combination products Antiretroviral combination products Clarithromycin Clozapine Cyclosporine Estrogen Derivatives:\u00a0In patients using combined oral contraceptive pills (OCP), the manufacturer recommends that patients use an alternative method of contraception, instead of or in\u00a0addition to OCP, during and until one month after completing modafinil therapy. Guanfacine Lurasidone Nimodipine Opioid medications (e.g., codeine, fentanyl, hydrocodone) Ranolazine Zolpidem"}
{"id": "article-37470_27", "title": "Modafinil -- Monitoring", "content": "Serum concentrations of modafinil may be decreased to a clinically significant extent in the presence of drugs that induce CYP3A4. These include rifampin, phenytoin, St. John\u2019s Wort, and efavirenz. Conversely, serum concentrations of modafinil may be increased to a clinically significant extent in the presence of drugs that inhibit CYP3A4. These include azole antifungals (ketoconazole, itraconazole), ritonavir, and clarithromycin.", "contents": "Modafinil -- Monitoring. Serum concentrations of modafinil may be decreased to a clinically significant extent in the presence of drugs that induce CYP3A4. These include rifampin, phenytoin, St. John\u2019s Wort, and efavirenz. Conversely, serum concentrations of modafinil may be increased to a clinically significant extent in the presence of drugs that inhibit CYP3A4. These include azole antifungals (ketoconazole, itraconazole), ritonavir, and clarithromycin."}
{"id": "article-37470_28", "title": "Modafinil -- Toxicity", "content": "Case reports of modafinil overdose/toxicity are rare. Clinical manifestations of modafinil overdose are relatively mild but may include hypertension, tachycardia, agitation, and/or psychosis. [23] The most\u00a0frequently reported clinical effects were tachycardia, insomnia, agitation, dizziness, and anxiety. About 20 percent of overdose cases require medical treatment. Symptoms typically respond to supportive therapy, although augmentation with benzodiazepines is occasionally required. Other treatments include diphenhydramine, beta-blockers, haloperidol, IV fluid hydration, nitroglycerin, epinephrine, benztropine, and promethazine based on precipitating symptoms. [24]", "contents": "Modafinil -- Toxicity. Case reports of modafinil overdose/toxicity are rare. Clinical manifestations of modafinil overdose are relatively mild but may include hypertension, tachycardia, agitation, and/or psychosis. [23] The most\u00a0frequently reported clinical effects were tachycardia, insomnia, agitation, dizziness, and anxiety. About 20 percent of overdose cases require medical treatment. Symptoms typically respond to supportive therapy, although augmentation with benzodiazepines is occasionally required. Other treatments include diphenhydramine, beta-blockers, haloperidol, IV fluid hydration, nitroglycerin, epinephrine, benztropine, and promethazine based on precipitating symptoms. [24]"}
{"id": "article-37470_29", "title": "Modafinil -- Enhancing Healthcare Team Outcomes", "content": "Modafinil is a\u00a0stimulant medication that is generally\u00a0safe, well-tolerated, and carries a low potential for abuse and dependence.\u00a0It is used to treat excessive daytime sleepiness associated with narcolepsy, sleep work shift disorder, and obstructive sleep apnea. It is often used in conjunction\u00a0with other medical and lifestyle treatments for these conditions. Most patients can safely receive modafinil, although it should be used cautiously\u00a0in patients with structural cardiac disease, severe hepatic impairment, or a history of psychosis/mania. Although no specific monitoring is recommended for patients on modafinil, nurses, pharmacists, and physicians should be aware of the possible\u00a0drug-drug interactions, including oral contraceptive pills. That is why the prescriber should consult with a pharmacist and conduct a thorough evaluation of all existing medications. Nursing should monitor patient results and also check for signs of adverse reactions at each visit. This interprofessional approach will optimize therapy with modafinil. [Level 5]", "contents": "Modafinil -- Enhancing Healthcare Team Outcomes. Modafinil is a\u00a0stimulant medication that is generally\u00a0safe, well-tolerated, and carries a low potential for abuse and dependence.\u00a0It is used to treat excessive daytime sleepiness associated with narcolepsy, sleep work shift disorder, and obstructive sleep apnea. It is often used in conjunction\u00a0with other medical and lifestyle treatments for these conditions. Most patients can safely receive modafinil, although it should be used cautiously\u00a0in patients with structural cardiac disease, severe hepatic impairment, or a history of psychosis/mania. Although no specific monitoring is recommended for patients on modafinil, nurses, pharmacists, and physicians should be aware of the possible\u00a0drug-drug interactions, including oral contraceptive pills. That is why the prescriber should consult with a pharmacist and conduct a thorough evaluation of all existing medications. Nursing should monitor patient results and also check for signs of adverse reactions at each visit. This interprofessional approach will optimize therapy with modafinil. [Level 5]"}
{"id": "article-37470_30", "title": "Modafinil -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Modafinil -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}